Cargando…

Non-diabetic urine glucose in idiopathic membranous nephropathy

This study aims to analyze the characteristics of idiopathic membranous nephropathy (iMN) with nondiabetic urine glucose during the follow-up. We retrospectively analyzed the data of 1313 patients who were diagnosed iMN. The prevalence of nondiabetic urine glucose during follow-up was 10.89%. There...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Lingling, Zuo, Ke, Le, Weibo, Lu, Manman, Liu, Zhihong, Xu, Weiwei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9278411/
https://www.ncbi.nlm.nih.gov/pubmed/35820795
http://dx.doi.org/10.1080/0886022X.2022.2094806
_version_ 1784746180628971520
author Liu, Lingling
Zuo, Ke
Le, Weibo
Lu, Manman
Liu, Zhihong
Xu, Weiwei
author_facet Liu, Lingling
Zuo, Ke
Le, Weibo
Lu, Manman
Liu, Zhihong
Xu, Weiwei
author_sort Liu, Lingling
collection PubMed
description This study aims to analyze the characteristics of idiopathic membranous nephropathy (iMN) with nondiabetic urine glucose during the follow-up. We retrospectively analyzed the data of 1313 patients who were diagnosed iMN. The prevalence of nondiabetic urine glucose during follow-up was 10.89%. There were significant differences between the patients with nondiabetic urine glucose and those without urine glucose in gender, hypertension ratio, proteinuria, N-acetyl-β-glucosaminidase, retinol binding protein, serum albumin, serum creatinine (Scr), cholesterol, triglyceride and positive anti-phospholipase A2 receptor antibody ratio, glomerular sclerosis ratio, acute and chronic tubular injury lesion at baseline. To exclude the influence of the baseline proteinuria and Scr, case control sampling of urine glucose negative patients was applied according to gender, baseline proteinuria and Scr. The proteinuria nonremission (NR) ratio was 45.83 versus 12.50% of the urine glucose positive group and case control group. Partial remission (PR) ratio of the two groups was 36.46 versus 23.96% and complete remission (CR) ratio was 19.79% versus 63.54%, respectively. Patients with urine glucose had higher risk of 50% estimated glomerular filtration rate (eGFR) reduction. Cox regression showed that urine glucose and baseline Scr were risk factors of 50% reduction of eGFR. Urine glucose remission ratio of the patients with proteinuria NR, PR, and CR was 13.33, 56.25, and 94.73% (p < 0.005). Patients who got urine glucose remission also had better renal survival. In conclusion, non-diabetic urine glucose was closely related to proteinuria. It could be applied as a tubular injury marker to predict renal function.
format Online
Article
Text
id pubmed-9278411
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Taylor & Francis
record_format MEDLINE/PubMed
spelling pubmed-92784112022-07-14 Non-diabetic urine glucose in idiopathic membranous nephropathy Liu, Lingling Zuo, Ke Le, Weibo Lu, Manman Liu, Zhihong Xu, Weiwei Ren Fail Clinical Study This study aims to analyze the characteristics of idiopathic membranous nephropathy (iMN) with nondiabetic urine glucose during the follow-up. We retrospectively analyzed the data of 1313 patients who were diagnosed iMN. The prevalence of nondiabetic urine glucose during follow-up was 10.89%. There were significant differences between the patients with nondiabetic urine glucose and those without urine glucose in gender, hypertension ratio, proteinuria, N-acetyl-β-glucosaminidase, retinol binding protein, serum albumin, serum creatinine (Scr), cholesterol, triglyceride and positive anti-phospholipase A2 receptor antibody ratio, glomerular sclerosis ratio, acute and chronic tubular injury lesion at baseline. To exclude the influence of the baseline proteinuria and Scr, case control sampling of urine glucose negative patients was applied according to gender, baseline proteinuria and Scr. The proteinuria nonremission (NR) ratio was 45.83 versus 12.50% of the urine glucose positive group and case control group. Partial remission (PR) ratio of the two groups was 36.46 versus 23.96% and complete remission (CR) ratio was 19.79% versus 63.54%, respectively. Patients with urine glucose had higher risk of 50% estimated glomerular filtration rate (eGFR) reduction. Cox regression showed that urine glucose and baseline Scr were risk factors of 50% reduction of eGFR. Urine glucose remission ratio of the patients with proteinuria NR, PR, and CR was 13.33, 56.25, and 94.73% (p < 0.005). Patients who got urine glucose remission also had better renal survival. In conclusion, non-diabetic urine glucose was closely related to proteinuria. It could be applied as a tubular injury marker to predict renal function. Taylor & Francis 2022-07-12 /pmc/articles/PMC9278411/ /pubmed/35820795 http://dx.doi.org/10.1080/0886022X.2022.2094806 Text en © 2022 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group. https://creativecommons.org/licenses/by/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) ), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Clinical Study
Liu, Lingling
Zuo, Ke
Le, Weibo
Lu, Manman
Liu, Zhihong
Xu, Weiwei
Non-diabetic urine glucose in idiopathic membranous nephropathy
title Non-diabetic urine glucose in idiopathic membranous nephropathy
title_full Non-diabetic urine glucose in idiopathic membranous nephropathy
title_fullStr Non-diabetic urine glucose in idiopathic membranous nephropathy
title_full_unstemmed Non-diabetic urine glucose in idiopathic membranous nephropathy
title_short Non-diabetic urine glucose in idiopathic membranous nephropathy
title_sort non-diabetic urine glucose in idiopathic membranous nephropathy
topic Clinical Study
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9278411/
https://www.ncbi.nlm.nih.gov/pubmed/35820795
http://dx.doi.org/10.1080/0886022X.2022.2094806
work_keys_str_mv AT liulingling nondiabeticurineglucoseinidiopathicmembranousnephropathy
AT zuoke nondiabeticurineglucoseinidiopathicmembranousnephropathy
AT leweibo nondiabeticurineglucoseinidiopathicmembranousnephropathy
AT lumanman nondiabeticurineglucoseinidiopathicmembranousnephropathy
AT liuzhihong nondiabeticurineglucoseinidiopathicmembranousnephropathy
AT xuweiwei nondiabeticurineglucoseinidiopathicmembranousnephropathy